Donor derived cell free DNA% is elevated with pathogens that are risk factors for acute and chronic lung allograft injury.
cfDNA
chronic lung allograft dysfunction
lung transplantation
transplant infection
Journal
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
13
08
2020
revised:
21
05
2021
accepted:
25
05
2021
pubmed:
5
8
2021
medline:
4
3
2022
entrez:
4
8
2021
Statut:
ppublish
Résumé
Acute and chronic forms of lung allograft injury are associated with specific respiratory pathogens. Donor-derived cell free DNA (ddcfDNA) has been shown to be elevated with acute lung allograft injury and predictive of long-term outcomes. We examined the %ddcfDNA values at times of microbial isolation from bronchoalveolar lavage (BAL). Two hundred and six BAL samples from 51 Lung Transplant Recipients (LTRs) with concurrently available plasma %ddcfDNA were analyzed along with microbiology and histopathology. Microbial species were grouped into bacterial, fungal, and viral and "higher risk" and "lower risk" cohorts based on historical association with downstream allograft dysfunction. Analyses were performed to determine pathogen category association with %ddcfDNA, independent of inter-subject variability. Presence of microbial isolates in BAL was not associated with elevated %ddcfDNA compared to samples without isolates. However, "higher risk" bacterial and viral microbes showed greater %ddcfDNA values than lower risk species (1.19% vs. 0.65%, p < 0.01), independent of inter-subject variability. Histopathologic abnormalities concurrent with pathogen isolation were associated with higher %ddcfDNA compared to isolation episodes with normal histopathology (medians 1.23% and 0.66%, p = 0.05). Assessments showed no evidence of correlation between histopathology or bronchoscopy indication and presence of higher risk vs. lower risk pathogens. %ddcfDNA is higher among cases of microbial isolation with concurrent abnormal histopathology and with isolation of higher risk pathogens known to increase risk of allograft dysfunction. Future studies should assess if %ddcfDNA can be used to stratify pathogens for risk of CLAD and identify pathogen associated injury prior to histopathology.
Sections du résumé
BACKGROUND
Acute and chronic forms of lung allograft injury are associated with specific respiratory pathogens. Donor-derived cell free DNA (ddcfDNA) has been shown to be elevated with acute lung allograft injury and predictive of long-term outcomes. We examined the %ddcfDNA values at times of microbial isolation from bronchoalveolar lavage (BAL).
METHODS
Two hundred and six BAL samples from 51 Lung Transplant Recipients (LTRs) with concurrently available plasma %ddcfDNA were analyzed along with microbiology and histopathology. Microbial species were grouped into bacterial, fungal, and viral and "higher risk" and "lower risk" cohorts based on historical association with downstream allograft dysfunction. Analyses were performed to determine pathogen category association with %ddcfDNA, independent of inter-subject variability.
RESULTS
Presence of microbial isolates in BAL was not associated with elevated %ddcfDNA compared to samples without isolates. However, "higher risk" bacterial and viral microbes showed greater %ddcfDNA values than lower risk species (1.19% vs. 0.65%, p < 0.01), independent of inter-subject variability. Histopathologic abnormalities concurrent with pathogen isolation were associated with higher %ddcfDNA compared to isolation episodes with normal histopathology (medians 1.23% and 0.66%, p = 0.05). Assessments showed no evidence of correlation between histopathology or bronchoscopy indication and presence of higher risk vs. lower risk pathogens.
CONCLUSION
%ddcfDNA is higher among cases of microbial isolation with concurrent abnormal histopathology and with isolation of higher risk pathogens known to increase risk of allograft dysfunction. Future studies should assess if %ddcfDNA can be used to stratify pathogens for risk of CLAD and identify pathogen associated injury prior to histopathology.
Identifiants
pubmed: 34344623
pii: S1053-2498(21)02326-3
doi: 10.1016/j.healun.2021.05.012
pmc: PMC8571060
mid: NIHMS1731211
pii:
doi:
Substances chimiques
Cell-Free Nucleic Acids
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1454-1462Subventions
Organisme : Intramural NIH HHS
ID : Z99 HL999999
Pays : United States
Informations de copyright
Copyright © 2021 International Society for Heart and Lung Transplantation. All rights reserved.
Références
Semin Respir Crit Care Med. 2006 Oct;27(5):544-51
pubmed: 17072802
Am J Respir Crit Care Med. 2007 Mar 1;175(5):507-13
pubmed: 17158279
Transpl Infect Dis. 2009 Oct;11(5):424-31
pubmed: 19659672
EBioMedicine. 2019 Feb;40:541-553
pubmed: 30692045
J Heart Lung Transplant. 2009 Feb;28(2):163-9
pubmed: 19201342
Semin Respir Crit Care Med. 2010 Apr;31(2):243-54
pubmed: 20354936
BMC Microbiol. 2018 Aug 20;18(1):88
pubmed: 30126365
J Am Soc Nephrol. 2017 Jul;28(7):2221-2232
pubmed: 28280140
J Heart Lung Transplant. 2017 Sep;36(9):1004-1012
pubmed: 28624139
Clin Infect Dis. 2019 Sep 13;69(7):1192-1197
pubmed: 30561555
J Heart Lung Transplant. 2011 Apr;30(4):361-74
pubmed: 21419994
Clin Transplant. 2013 Jan-Feb;27(1):E64-71
pubmed: 23278569
J Heart Lung Transplant. 2009 Sep;28(9):888-93
pubmed: 19716040
Clin Transplant. 2019 Sep;33(9):e13511
pubmed: 30817023
Am J Transplant. 2017 May;17(5):1304-1312
pubmed: 27615811
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13336-41
pubmed: 26460048
Transplant Proc. 2018 Sep;50(7):2064-2069
pubmed: 30177110
J Clin Virol. 2015 Mar;64:1-5
pubmed: 25728070
Eur Respir J. 2008 May;31(5):1037-45
pubmed: 18256072
J Heart Lung Transplant. 2016 Apr;35(4):397-406
pubmed: 27044531
Transplantation. 2008 Mar 15;85(5):771-4
pubmed: 18337673
J Thorac Cardiovasc Surg. 1998 Oct;116(4):617-23
pubmed: 9766590
Transplant Proc. 2020 Sep;52(7):2149-2154
pubmed: 32446686
Curr Infect Dis Rep. 2016 Jul;18(7):21
pubmed: 27221821
N Engl J Med. 2007 Dec 20;357(25):2601-14
pubmed: 18094380
Transplantation. 2020 Jun;104(6):1280-1286
pubmed: 31568275
J Heart Lung Transplant. 2018 Jul;37(7):925-932
pubmed: 29500138
Am J Transplant. 2017 Apr;17(4):856-879
pubmed: 28117944
Am J Transplant. 2011 May;11(5):1071-8
pubmed: 21521473
Am J Transplant. 2020 Apr;20(4):1028-1038
pubmed: 31677358
J Heart Lung Transplant. 1995 May-Jun;14(3):479-85
pubmed: 7654733
Am J Respir Crit Care Med. 2004 Jul 15;170(2):181-7
pubmed: 15130908
J Heart Lung Transplant. 2020 Apr;39(4):379-388
pubmed: 32033844
Transpl Infect Dis. 2020 Dec;22(6):e13422
pubmed: 32686323
Am J Transplant. 2015 Mar;15(3):792-9
pubmed: 25683785